In this study, researchers sought to investigate the psychometric properties of the ASRS and WURS in a well-characterized sample of adult ADHD patients and population controls.
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
Researchers sought to identify the major leading nonpharmaceutical intervention for ADHD cognitive symptomology, as well as which cognitive symptoms are most amenable to change.
The New Drug Application (NDA) for viloxazine hydrochloride (SPN-812; Supernus Pharmaceuticals), a serotonin norepinephrine modulating agent, has been submitted to the Food and Drug Administration (FDA) for the treatment of pediatric patients with attention deficit hyperactivity disorder (ADHD).
Prevention programs may improve long-term outcomes in children and adolescents by addressing pre-existing vulnerabilities that increase the risk for exposure to bullying.
This research rejects any association between increased risk for ADHD and changes in children’s microbiota related to cesarean delivery or antibiotic use.
